Clinical trials: Other Cancer
Hepatocellular Carcinoma, Prostate Cancer
LTFU for All Cell and Gene Therapy Studies
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Trial name
- LOCUS (NCT06194461)
- Testing
- AZD5851, AZD0754
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Head and Neck Squamous Cell Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- NCT06437522
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Breast Cancer
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT07169994
- Testing
- YL202 for injection; Toripalimab injection, YL202 for injection; Furmonertinib Mesilate Tablets
- Where
- 20 sites in China
- Volunteers
- 414 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors Which Are cMET-dependent
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or…
- Trial name
- NCT03040973
- Testing
- Capmatinib, Nazartinib, Gefitinib
- Where
- 15 sites in United States, Belgium and 9 more
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with…
- Trial name
- NCT06191796
- Testing
- zanzalintinib, AB521, Nivolumab
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Exelixis
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
KRAS Mutant Solid Tumors
TLN-372 in Advanced KRAS Mutant Solid Tumors
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid…
- Trial name
- NCT07204340
- Testing
- TLN-372, TLN-372 in combination with cetuximab, TLN-372 in combination with pembrolizumab
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 270 people
- Sponsor
- Treeline Biosciences, Inc.
Advanced Solid Tumor
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07256782
- Testing
- QLC5508, QL1706, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Osteosarcoma, Soft Tissue Sarcoma (STS)
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma.
- Trial name
- NCT06699576
- Testing
- HS-20093, Anlotinib, Epirubicin
- Volunteers
- 448 people
- Sponsor
- Hansoh BioMedical R&D Company
Early-Stage Non-Small Cell Lung Cancer
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
- Trial name
- NCT07871214
- Testing
- Pumitamig, Carboplatin, Cisplatin
- Where
- 50 sites in United States, Australia and 12 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus The study will also…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT03564340
- Testing
- Ubamatamab, Cemiplimab, Sarilumab
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 890 people
- Sponsor
- Regeneron Pharmaceuticals
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 14 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.
Systemic Fungal Infections
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with…
- Trial name
- MYCOS (NCT01686607)
- Testing
- Parenteral micafungin application, Other parenteral antifungal drugs
- Where
- 6 sites in United States
- Volunteers
- 40,110 people
- Sponsor
- Astellas Pharma Europe B.V.
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy